Finish biotech startup Solu has raised $1 million in a round led by Oura-backer Lifeline Ventures. Solu is working with Stanford University to solve the growing problem of antibiotic resistance. A startup working with Stanford University to combat the issue of antibiotic resistance has secured $1 million in fresh funds. Antibiotic resistance is when bacteria start to resist the effect of medication, evolving into 'superbugs'. The World Health Organization has tipped antibiotic resistance to be one of the biggest threats to health and food security.

---

Persons: Sam Sihvonen, Sihvonen, Paul L, Solu, Kristian Ranta, Lauri Sippola Organizations: Oura, Lifeline Ventures, Solu, Stanford University, World Health, Stanford University's Medical, DoorDash, Meru Health, Kaiku Health Locations: Finland, Finnish, Meru